Clinical Trials
29 trialsNCT06710756 2026-06-05
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
Phase 1/2 Recruiting
NCT07407582 2026-06-05
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
Phase 1/2 Recruiting
NCT05768139 2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06657222 2026-05-27
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Phase 1/2 Recruiting
NCT07339176 2026-05-14
OP-NEU-101
Onchilles Pharma Inc
Phase 1/2 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT06993844 2026-05-06
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Phase 1/2 Recruiting
NCT07213934 2026-04-15
Phase I/ II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma
University of Cincinnati
Phase 1/2 Recruiting
NCT04585750 2026-03-12
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
Phase 1/2 Recruiting
NCT06096038 2026-02-20
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04930432 2026-02-10
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Betta Pharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT06319963 2026-02-02
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Theravectys S.A.
Phase 1/2 Recruiting
NCT07292168 2026-01-21
TAGNOT
Kidney Cancer Research Bureau
Phase 1/2 Recruiting
NCT03556228 2025-12-11
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
Phase 1/2 Recruiting
NCT05706129 2025-10-20
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
ITM Oncologics GmbH
Phase 1/2 Recruiting
NCT04954599 2025-10-07
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Maastricht University Medical Center
Phase 1/2 Recruiting
NCT05941507 2025-09-24
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Phase 1/2 Recruiting
NCT05838729 2025-09-17
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Coordination Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT05592626 2025-07-09
START-001
Marengo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05944237 2025-06-08
HTL0039732 in Participants With Advanced Solid Tumours
Cancer Research UK
Phase 1/2 Recruiting
NCT05144698 2025-05-14
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
Phase 1/2 Recruiting
NCT06494943 2025-02-25
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC
Fudan University
Phase 1/2 Recruiting
NCT06549946 2025-01-30
IXACT
Psivac Ltd
Phase 1/2 Recruiting
NCT05156060 2024-10-21
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Vanderbilt-Ingram Cancer Center
Phase 1/2 Recruiting
NCT05187338 2024-06-25
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Second Affiliated Hospital of Guangzhou Medical University
Phase 1/2 Recruiting
NCT05955105 2024-05-21
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Innolake Biopharm
Phase 1/2 Recruiting
NCT06265025 2024-03-21
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
GeneMedicine Co., Ltd.
Phase 1/2 Recruiting
NCT04729543 2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2 Recruiting